Mature Response Data from A Phase 2 study of PI3K-Delta Inhibitor Idelalisib in patients with Double (Rituximab and Alkylating agent)-Refractory indolent B-cell Non-Hodgkin Lymphoma (iNHL)

K. Linton, A. Davies, A.K. Gopal, B.S. Kahl, S. de Vos, N.D. Wagner-Johnston, S.J. Schuster, W.J. Jurczak, I.W. Flinn, C.R. Flowers, P. Martin, A. Viardot, K.A. Blum, A.H. Goy, [Unknown] Gribben, H-T Arkenau, R. Johnson, P.L. Zinzani, M. Dreyling, C. RennerL. Holes, D. Li, R.D. Dansey, W.R. Godfrey, G.A. Salles

    Research output: Contribution to conferencePoster

    Original languageEnglish
    Publication statusPublished - Apr 2014
    EventBritish Haematology Society Annual Meeting - Birmingham, UK
    Duration: 1 Jan 1824 → …


    ConferenceBritish Haematology Society Annual Meeting
    CityBirmingham, UK
    Period1/01/24 → …

    Cite this